Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer

D. Vrana, V. Hlavac, V. Brynychova, R. Vaclavikova, C. Neoral, J. Vrba, R. Aujesky, M. Matzenauer, B. Melichar, P. Soucek,

. 2018 ; 19 (3) : . [pub] 20180315

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033243

The prognosis of esophageal cancer (EC) is poor, despite considerable effort of both experimental scientists and clinicians. The tri-modality treatment consisting of neoadjuvant chemoradiation followed by surgery has remained the gold standard over decades, unfortunately, without significant progress in recent years. Suitable prognostic factors indicating which patients will benefit from this tri-modality treatment are missing. Some patients rapidly progress on the neoadjuvant chemoradiotherapy, which is thus useless and sometimes even harmful. At the same time, other patients achieve complete remission on neoadjuvant chemoradiotherapy and subsequent surgery may increase their risk of morbidity and mortality. The prognosis of patients ranges from excellent to extremely poor. Considering these differences, the role of drug metabolizing enzymes and transporters, among other factors, in the EC response to chemotherapy may be more important compared, for example, with pancreatic cancer where all patients progress on chemotherapy regardless of the treatment or disease stage. This review surveys published literature describing the potential role of ATP-binding cassette transporters, the genetic polymorphisms, epigenetic regulations, and phenotypic changes in the prognosis and therapy of EC. The review provides knowledge base for further research of potential predictive biomarkers that will allow the stratification of patients into defined groups for optimal therapeutic outcome.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033243
003      
CZ-PrNML
005      
20190710124500.0
007      
ta
008      
181008s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms19030868 $2 doi
035    __
$a (PubMed)29543757
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vrana, David $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 976/3, 77515 Olomouc, Czech Republic. davvrana@gmail.com.
245    10
$a ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer / $c D. Vrana, V. Hlavac, V. Brynychova, R. Vaclavikova, C. Neoral, J. Vrba, R. Aujesky, M. Matzenauer, B. Melichar, P. Soucek,
520    9_
$a The prognosis of esophageal cancer (EC) is poor, despite considerable effort of both experimental scientists and clinicians. The tri-modality treatment consisting of neoadjuvant chemoradiation followed by surgery has remained the gold standard over decades, unfortunately, without significant progress in recent years. Suitable prognostic factors indicating which patients will benefit from this tri-modality treatment are missing. Some patients rapidly progress on the neoadjuvant chemoradiotherapy, which is thus useless and sometimes even harmful. At the same time, other patients achieve complete remission on neoadjuvant chemoradiotherapy and subsequent surgery may increase their risk of morbidity and mortality. The prognosis of patients ranges from excellent to extremely poor. Considering these differences, the role of drug metabolizing enzymes and transporters, among other factors, in the EC response to chemotherapy may be more important compared, for example, with pancreatic cancer where all patients progress on chemotherapy regardless of the treatment or disease stage. This review surveys published literature describing the potential role of ATP-binding cassette transporters, the genetic polymorphisms, epigenetic regulations, and phenotypic changes in the prognosis and therapy of EC. The review provides knowledge base for further research of potential predictive biomarkers that will allow the stratification of patients into defined groups for optimal therapeutic outcome.
650    _2
$a ABC transportéry $x genetika $x metabolismus $7 D018528
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a epigeneze genetická $7 D044127
650    _2
$a nádory jícnu $x genetika $x metabolismus $x terapie $7 D004938
650    _2
$a lidé $7 D006801
650    _2
$a neoadjuvantní terapie $x metody $7 D020360
650    _2
$a polymorfismus genetický $7 D011110
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hlavac, Viktor $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. viktor.hlavac@lfp.cuni.cz.
700    1_
$a Brynychova, Veronika $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. veronika.brynychova@lfp.cuni.cz.
700    1_
$a Vaclavikova, Radka $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. radka.vaclavikova@lfp.cuni.cz.
700    1_
$a Neoral, Cestmir $u Department of Surgery, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 976/3, 77515 Olomouc, Czech Republic. neoralc@fnol.cz.
700    1_
$a Vrba, Jiri $u Department of Surgery, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 976/3, 77515 Olomouc, Czech Republic. j.vrba@upol.cz.
700    1_
$a Aujesky, Rene $u Department of Surgery, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 976/3, 77515 Olomouc, Czech Republic. rene.aujesky@fnol.cz.
700    1_
$a Matzenauer, Marcel $7 xx0237901 $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 976/3, 77515 Olomouc, Czech Republic. Marcel.Matzenauer01@upol.cz.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 976/3, 77515 Olomouc, Czech Republic. bohuslav.melichar@upol.cz.
700    1_
$a Soucek, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 32300 Pilsen, Czech Republic. pavel.soucek@lfp.cuni.cz. Department of Surgery, Faculty Hospital Pilsen, Alej Svobody 80, 30460 Pilsen, Czech Republic. pavel.soucek@lfp.cuni.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 19, č. 3 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29543757 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20190710124700 $b ABA008
999    __
$a ok $b bmc $g 1340858 $s 1030237
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 3 $e 20180315 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace